Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
Dilip Shanghvi to continue as the Executive Chairman of the Board
Now approved for both acute and chronic HCV in adults and children aged 3 and above
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Ranks among the top 15% companies globally
The company received 1 (One) observation in the Form-483
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
Subscribe To Our Newsletter & Stay Updated